RELPREMA
DEAD

Serial Number

90533556

Owner

ALLERGAN SALES, LLC

Attorney

Cheryl A. Withycombe

Filing Date

Feb 18, 2021

Add to watchlist:

No watchlists yet
View on USPTO

RELPREMA Trademark

Serial Number: 90533556

RELPREMA is a trademark filed by ALLERGAN SALES, LLC on February 18, 2021. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

ALLERGAN SALES, LLC (490 trademarks)

5 GIRALDA FARMS
MADISON, NJ 07940

Entity Type: 16

Trademark Details

Filing Date

February 18, 2021

Registration Date

Not Registered

Published for Opposition

April 5, 2022

Goods & Services

Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; hormone replacement therapy preparations; pharmaceutical preparations for the prevention of preterm birth or pregnancy; pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; pharmaceutical preparations for the treatment and prevention of osteoporosis; pharmaceutical preparations for the treatment and prevention of endometriosis; pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; iron chelating pharmaceutical preparations; fertility enhancing pharmaceutical preparations; pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; pharmaceutical preparations and medicines for the treatment of sensory organ disorders; pharmaceutical preparations and medicines for the treatment of central nervous system disorders; pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; pharmaceutical preparations and medicines for the treatment of circulatory system disorders; pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; antibiotics; antifungal preparations; antivirals and antiprotozoals; pharmaceutical preparations for the prevention and treatment of bacterial infections; pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; pharmaceutical preparations for the prevention and treatment of hypertension; preparations for the prevention and treatment of Alzheimer's disease, dementia, aids-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; neuroprotective agent; antidepressants; pharmaceutical preparations, namely, antipsychotics; coronary vasodilating agents; pharmaceutical preparations for the treatment of hypothyroidism; pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Jan 3, 2023 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Jan 2, 2023 ABN6
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
May 31, 2022 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 5, 2022 NPUB
PUBLISHED FOR OPPOSITION
Apr 5, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 16, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 3, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 2, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 2, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 2, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 16, 2021 GNRN
NON-FINAL ACTION E-MAILED
Sep 16, 2021 GNRT
NON-FINAL ACTION WRITTEN
Sep 16, 2021 CNRT
ASSIGNED TO EXAMINER
Sep 14, 2021 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 19, 2021 NWOS
NEW APPLICATION ENTERED
Feb 22, 2021 NWAP